Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | IGF2R | P11717 | 4/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14258148 | 1.00 | FBP1 (0.50) | FBP1AMDHD2ADORA1IGF2RP2RY14 | |
| SCHEMBL10295575 | 0.85 | FBP1 (0.53) | FBP1AMDHD2IGF2RP2RY14P2RY2 | |
| SCHEMBL15177582 | 0.83 | FBP1 (0.50) | FBP1AMDHD2ADORA1IGF2RP2RY14 | |
| SCHEMBL13857407 | 0.82 | FBP1 (0.46) | FBP1AMDHD2ADORA1IGF2RP2RY14 | |
| SCHEMBL14375349 | 0.82 | FBP1 (0.46) | FBP1AMDHD2ADORA1IGF2RP2RY14 | |
| SCHEMBL13449608 | 0.82 | IGF2R (0.44) | FBP1IGF2R | |
| SCHEMBL12837374 | 0.82 | IGF2R (0.44) | FBP1IGF2R | |
| SCHEMBL19591957 | 0.81 | FBP1 (0.49) | FBP1AMDHD2ADORA1IGF2RP2RY14 | |
| SCHEMBL15493956 | 0.81 | FBP1 (0.49) | FBP1AMDHD2ADORA1IGF2RP2RY14 | |
| SCHEMBL15999943 | 0.81 | FBP1 (0.49) | FBP1AMDHD2ADORA1IGF2RP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080057107-A1 | COMPOSITIONS FOR VAGINAL TREATMENT | KIMBERLY-CLARK WORLDWIDE, INC. | 2008-03-06 | — | — | US | disclosed |
| US-7276486-B2 | Compositions for vaginal treatment | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057107-A1 | COMPOSITIONS FOR VAGINAL TREATMENT | MAN2A1, MUC1, MAN2B2 | FBP1 207/4885AMDHD2 209/4885ADORA1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.